Knocking-Out Concentrations of HIV-1-Specific Inhibitors Completely Suppress HIV-1 Infection and Prevent the Emergence of Drug-Resistant Virus

Virology

Volumn 196, Issue 2, 1993, Pages 576-585

  Balzarini, Jan ^a   Karlsson, Anna ^b   Pérez Pérez, Maria Jésus ^c   Camarasa, Maria José ^c   De Clercq, Erik ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b KAROLINSKA INSTITUTE   (Sweden)

^c INSTITUTO DE QUÍMICA MÉDICA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1H INDOL 2 YLCARBONYL) 4 [3 (ISOPROPYLAMINO)PYRIDINYL]PIPERAZINE; 3 [(4,7 DICHLORO 2 BENZOXAZOLYLMETHYL)AMINO] 5 ETHYL 6 METHYL 2(1H) PYRIDONE; 9 CHLORO 4,5,6,7 TETRAHYDRO 5 METHYL 6 (3 METHYL 2 BUTENYL)IMIDAZO[4,5,1 JK][1,4]BENZODIAZEPINE 2(1H) THIONE; ADEFOVIR; ANTIVIRUS AGENT; DIDANOSINE; L 697 661; NEVIRAPINE; NUCLEOSIDE DERIVATIVE; PYRIDINONE; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CONTROLLED STUDY; DRUG RESISTANCE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL;

ANTIVIRAL AGENTS; BASE SEQUENCE; BENZODIAZEPINES; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MICROBIAL; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMAN; IMIDAZOLES; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; NEVIRAPINE; PIPERAZINES; PYRIDINES; PYRIDONES; REVERSE TRANSCRIPTASE INHIBITORS; RNA-DIRECTED DNA POLYMERASE; SEQUENCE ANALYSIS; SUPPORT, NON-U.S. GOV'T; THYMIDINE; THYMINE; VIRUS REPLICATION;

EID: 0027363224     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1006/viro.1993.1513     Document Type: Article

References (42)

1. Baba, M, Tanaka, H., De Clercq, E., Pauwels, R., Balzarini, J., Schols, D., Nakashima, H., Perno, C.-F., Walker, R. T., and Miya-saka, T. (1989). Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative. Biochem. Biophys. Res. Commun. 165, 1375-1381.
2. Balzarini, J., Herdewijn, P., and De Clercq, E. (1989). Differential patterns of intracellular metabolism of 2’, 3’-didehydro-2’, 3-dideox-ythymidine (D4T) and 3’-azido-2’, 3’-dideoxythymidine (AZT), two potent anti-HIV compounds. J. Biol, Chem. 264, 6127-6133.
3. Balzarini, J., Hao, Z., Herdewijn, P., Johns, D. G., and De Clercq, E. (1991). Intracellular metabolism and mechanism of anti-retrovirus action of 9-(2-phosphonylmethoxyethyf)adenine, a potent anti-hu-man immunodeficiency virus compound. Proc. Natl. Acad. Set. USA 88, 1499-1503.
4. Balzarini, J., Pérez-Pérez, M.-J., San-Félix, A., Schols, D., Perno, C.-F., Vandamme, A.-M., Camarasa, M.-j., and De Clercq, E. (1992a). 2’, 5’-Bis-O-(tert-butyldimethylsilyl)-3’-spiro-5”-(4”-amino-r, 2*-oxathiole-2”, 2”-dioxide)pyrimidine (TSAO) nucleoside analogues: Highly selective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase. Proc. Natl. Acad, Sei. USA 89, 4392-4396.
5. Balzarini, J., Pérez-Pérez, M.-J., San-Félix, A., Velazquez, S., Camarasa, M.-J., and De Clercq, E. (1992b). [2’, 5’-Bis-O-(tert-butyldi-methylsilyl)]-3’-spiro-5”-(4”-amino-1”, 2”-oxathiole-2”, 2”-dioxide) (TSAO) derivatives of purine and pyrimidine nucleosides as potent and selective inhibitors of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 36, 1073-1080.
6. Balzarini, J., Karlsson, A., Pérez-Pérez, M.-J., Camarasa, M.-J., and De Clercq, E. (1992c). Emergence of drug-resistant human immunodeficiency virus type 1 (HIV-1) mutants following combination of different HIV-1-specific reverse transcriptase inhibitors. Arch. Int. Biochem. Biophys. 101, B2.
7. Balzarini, J., Karlsson, A., Pérez-Pérez, M.-J., Vrang, L, Walbers, J., Zhang, H., Öberg, B., Vandamme, A.-M., Camarasa, M.-J., and De Clercq, E. (1993a). HIV-1-specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptase. Virology 192, 246-253.
8. Balzarini, J., Velazquez, S., Karlsson, A., Pérez-Pérez, M.-J., San-Félix, A., Camarasa, M.-J., and De Clercq, E. (1993b). Human immunodeficiency virus type 1-specific (2’, 5’-bis-O-(terf-butyldimethylsilyl)-O-D-ribofuranosyl]-3’-spiro-5”-(4”-amino-r, 2”-oxathiole-2”, 2”-dioxide)-purine analogues show a resistance spectrum that is different from that of the human immunodeficiency virus type 1-specific non-nucleoside analogues. Mol. Pharmacol. 43, 109-114.
9. Balzarini, J., Karlsson, A., Vandamme, A.-M., Pérez-Pérez, M.-J., Zhang, H., Vrang, L, Öberg, B., Bäckbro, K., Unge, T., San-Félix, A., Velazquez, S., Camarasa, M.-J., and De Clercq, E. (1993c). Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the novel class of HIV-1-specific TSAO nucleoside analogues retain sensitivity to HIV-1-specific non-nucleoside inhibitors. Proc. Natl. Acad. Set. USA. in press.
10. Camarasa, M.-J., Pérez-Pérez, M.-J., San-Félix, A., Balzarini, J., and De Clercq, E. (1992). 3’-Spiro nucleosides, a new class of specific human immunodeficiency virus type 1 inhibitors: synthesis and antiviral activity of [2., 5’-bis-0-(ferf-butyldimethylsilyl)-l8-D-xyiO’ and-ribofuranose]-3’-spiro-5”-[4”-amino-r, 2”-oxathiole-2”, 2”-dioxide] (TSAO) pyrimidine nucleosides. J Med. Chem. 35, 2721-2727.
11. Chow, Y.-K., Hirsch, M. S., Merrill, D. P., Bechtel, L J., Eron, J. J., Kaplan, J. C., and D’Aquila, R.T. (1993). Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy. Nature361, 650-654.
12. De Vreese, K., Vandamme, A.-M., Schols, D, Pauwels, R., Debyser, Z, Desmyter, J., De Clercq, E, and Anné, J. (1992). Influence of initial conditions on the development of resistance to TIBO derivatives in cell culture. Abstracts of the HIV Drug-Resistance Workshop, Noordwijk, The Netherlands, 16-18 July 1992, p. 10.
13. Dueweke, T. J., Kezdy, F. J, Waszak, G. A., Deibel, M. R., Jr., and Tarpley, W. G. (1992). The binding of a novel bis(heteroaryl)piper-azine mediates inhibition of human immunodeficiency virus type 1 reverse transcriptase, J. Biol. Chem. 267, 27-30.
14. Emini, E. A., Schleif, W. A., Byrnes, V. W., Condra, J. H, Sardanal, V. V., Kappes, J. C-, Saag, M, and Shaw, G. (1992). In vitro and in vivo derivation of HIV-1 variants resistant to inhibition by the nonnucleoside reverse transcriptase inhibitor L-697, 661. Abstracts of the HIV Drug-Resistance Workshop, Noordwijk, The Netherlands, 16-18 July 1992, p. 14.
15. Field, H. (ed.) (1992). Nevirapine and resistance. Int. Antiviral News 1, 2.
16. Furman, P. A., Fyfe, J. A., St Clair, M. H, Weinhold, K, Rideout, J. L, Freeman, G. A., Nusinoff Lehrman, S., Bolognesi, D. P., Broder, S., Mitsuya, H, and Barry, D. W. (1986). Phosphorylation of 3’-azido-3’-deoxythymidine and selective interaction of the 5’-triphosphate with immunodeficiency virus reverse transcriptase. Proc. Natl. Acad. Set. USA 83, 8333-8337.
17. Gao, Q., Gu, Z., Parniak, M. A., Li, X., and Wainberg, M. A. (1992). In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3’-azido-3’-deoxythymidine and 2’, 3’-dideoxyinosine. J. Virol 66, 12-19.
18. Goldman, M. E., Nunberg, J. H., O’Brien, J. A., Quintero, J C., Schleif, W. A., Freund, K. F., Gaul, S. L, Saari, W. S., Wai, J. S., Hoffman, J. M., Anderson, P. S., Hupe, D. J., Emini, E. A., and Stern, A. M.(1991). Pyridinone derivatives: Specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proc. Natl. Acad. Scl. USA 88, 6863-6867.
19. Kellam, P, Boucher, C. A. B., and Larder, B. A. (1992). Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc. Natl Acad. Scl USA 89, 1934-1938.
20. Koup, R. A., Merluzzi, V. J., Hargrave, K. D, Adams, J., Grozinger, K., Eckner, R. J., and Sullivan, J. L. (1991). Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by the dipyrido-diazepinone BI-RG-587. J. Infect. Dis. 163, 966-970.
21. Kukla, M. J., Breslin, H. J., Pauwels, R., Fedde, C. L, Miranda, M, Scott, M. K., Sherrill, R. G., Raeymaekers, A., Van Gelder, J., Andries, K, Janssen, M. A. C., DeClercq, E., and Janssen, P. A.J. (1991). Synthesis and anti-HIV-1 activity of 4, 5, 6, 7-tetrahydro-5-methylimidazo[4, 5, 1-jk][1, 4]benzodiazepin-2(lH)-one(TIb0)deriv-atives. J. Med. Chem. 34, 746-751.
22. Larder, B. A., and Kemp, S. D. (1989). Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246, 1155-1158.
23. Larder, B. A., Darby, G., and Richman, D. (1989). HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243, 1731-1734.
24. Maass, G., Immendoerfer, U., Leser, U, Pfaff, E., Goody, R, and Koenig, B. (1992), Viral resistance to the thiazolo-isoindolinones, a new class of non-nucleoside inhibitors of HIV-1 reverse transcriptase. Abstracts of the HIV Drug-Resistance Workshop, Noordwijk, The Netherlands, 16-18 July 1992, p. 29.
25. Mellors, J. W., Dutschman, G. E, Im, G.-J., Tramontano, E, Winkler, S. R, and Cheng, Y.-C. (1992). in vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase. Mol. Pharmacol. 41, 446-451.
26. Mellors, J. W., Im, G.-J., Tramontano, E., Winkler, S. R., Medina, D. J., Dutschman, G. E., Bazmi, H. Z., Piras, G., Gonzalez, C. J., and Cheng, Y.-C. (1993). A single conservative amino acid substitution in the reverse transcriptase of human immunodeficiency virus-1 confers resistance to (+) (5S)-4, 5, 6, 7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo[4, 5, 1-jk]-[1, 4]benzodiazepin-2(1H)-thione (TIBO 82150). Mol. Pharmacol. 43, 11-16.
27. Merluzzi, V. J., Hargrave, K. D., Labodia, M., Grozinger, K., Skoog, M., Wu, J. C., Shih, C.-K., Eckner, K., Hattox, S., Adams, J., Rosenthal, A. S., Faanes, R., Eckner, R. J., Koup, R. A., and Sullivan, J. L. (1990). Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 250, 1411-1413.
28. Miyasaka, T., Tanaka, H., Baba, M, Hayakawa, H., Walker, R. T., Balzarini, J, and De Clercq, E. (1989). A novel lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thy-mine. J. Med. Chem. 32, 2507-2509.
29. Nunberg, J. H., Schleif, W. A., Boots, E. J., O’Brien, J. A., Quintero, J. C., Hoffman, J. M., Emini, E. A., and Goldman, M. E. (1991). Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. J. Virol. 65, 4887-4892.
30. Pauwels, R., Andres, K., Desmyter, J., Schols, D., Kukla, M. J., Breslin, H J, Raeymaeckers, A., Van Gelder, J, Woestenborghs, R., HEYKANTS, J., SCHELLEKENS, K., JANSSEN, M. A. C-, DeClercq, E., and Janssen, P. A. J. (1990). Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 343, 470-474.
31. Pauwels, R., Andres, K., Debyser, Z., Van Daele, P., Schols, D., Vandamme, A.-M., Stoffels, P., De Vreese, K, Woestenborghs, R., Janssen, C. G. M., Anné, J., Cauwenbergh, G., Desmyter, J., Heykants, J, Janssen, M. A. C., De Clercq, E., and Janssen, P. A. J. (1993). Potent and highly selective HIV-1 inhibition by a new series of a-anilino phenyl acetamide (a-APA) derivatives targeted at HIV-1 reverse transcriptase. Proc. Natl. Acad. Sei. USA90, 1711-1715.
32. Pérez-Pérez, M. J., San-Félix, A., Balzarini, J., De Clercq, E., and Camarasa, M. J. (1992). TSAO Analogues. Stereospecific synthesis and anti-HIV-1 activity of 1-[2’, 5’-bis-O-(tert-butyldimethylsilyl)-β-D-ribofuranosyl]-3’-spiro-5’-(4”-amino-1”, 2”-oxathiole-2”, 2”-diox-ide) pyrimidine and pyrimidine-modified nucleosides. J. Med. Chem. 35, 2988-2995.
33. Pialoux, G., Youle, M., Dupont, B., Gazzard, B., Cauwenbergh, G. F. M. J., Stoffels, P. A. M., Davies, S., De Saint Martin, J, and Janssen, P. A. J. (1991). Pharmacokinetics of R82913 in patients with AIDS or AIDS-related complex. Lancet 338, 140-143.
34. Poppe, S. M., Dueweke, T. J., Chen, I. S. Y, and Tarpley, W. G. (1992). Development of resistance to the BHAP non-nucleoside HIV-1 RT inhibitors. Abstracts of the HIV Drug-Resistance Workshop, Noordwijk, The Netherlands, 16-18 July 1992, p. 9.
35. Richman, D., Shih, C.-K., Lowy, I., Rose, J., Prodanovich, P, Goff, S., and Griffin, J. (1991). Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc. Natl. Acad. Sei. USA 88, 11241-11245.
36. Richman, D., and the ACTG 164/168 Study Team (1992). The emergence of nevirapine resistance in clinical trials. Abstracts of the HIV Drug-Resistance Workshop, Noordwijk, The Netherlands, 16-18 July 1992, p. 13.
37. Romero, D. L, Busso, M, Tan, C.-K., Reusser, F., Palmer, J. R, Poppe, S. M., Aristoff, P. A., Downey, K. M, So, A. G., Resnick, L, and Tarpley, W. G. (1991). Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication. Proc. Natl. Acad. Sei. USA 88, 8806-8810.
38. Saari, W. S., Hoffman, J. M., Wai, J. S., Fisher, T. E., Rooney, C. S., Smith, A. M., Thomas, C. M., Goldman, M. E., O’Brien, J. A., Nunberg, J. N, Quintero, J. C., Schleif, W. A., Emini, E. A., Stern, A. M, and Anderson, P. S. (1991). 2-Pyridinone derivatives: A new class of nonnucleoside, HIV-1-specific reverse transcriptase inhibitors. J. Med. Chem. 34, 2922-2925.
39. Sardana, V. V., Emini, E. A., Gotlib, L, Graham, D. J., Lineberger, D. W, Long, W. J., Schlabach, A. J., Wolfgang, J. A., and Con-dra, J. H. (1992). Functional analysis of HIV-1 reverse transcriptase amino acids involved in resistance to multiple nonnucleoside inhibitors. J. Biol. Chem. 267, 17526-17530.
40. St Clair, M. H., Richards, C. A, Spector, T., Weinhold, K. J., Miller, W. H., Langlais, A. J., and Furman, P. A. (1987). 3’-Azido-3’-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase. An-timicrob. Agents Chemother. 31, 1972-1977.
41. St Clair, M. H, Martin, J. L, Tudor-Williams, G, Bach, M. C., Vavro, C. L, King, D. M., Kellam, P, Kemp, S. D., and Larder, B. A. (1991). Resistance to ddl and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 253, 1557-1559.
42. Wu, J. C, Warren, T. C., Adams, J., Proudfoot, J., Skiles, J., Ragha-van, P., Perry, C., Potocki, I., Farina, P. R., and Grob, P. M. (1991). A novel dipyridodiazepinone inhibitor of HIV-1 reverse transcriptase acts through a nonsubstrate binding site. Biochemistry30, 2022-2026